SARS-CoV-2 Infection and Outcomes in Children with Inflammatory Bowel Diseases: A Systematic Review
Abstract
:1. Introduction
2. Materials and Methods
2.1. Search Strategy—Databases
2.2. Selection Criteria
2.3. Study Selection and Data Extraction
3. Results
3.1. Study Characteristics
3.2. IBD Disease and COVID-19
3.3. IBD Disease Activity and COVID-19
3.4. IBD Medication and COVID-19
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- WHO. Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int (accessed on 27 October 2022).
- Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Inglesby, P.; et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020, 584, 430–436. [Google Scholar] [CrossRef] [PubMed]
- Mantovani, A.; Rinaldi, E.; Zusi, C.; Beatrice, G.; Saccomani, M.D.; Dalbeni, A. Coronavirus disease 2019 (COVID-19) in children and/or adolescents: A meta-analysis. Pediatr. Res. 2021, 89, 733–737. [Google Scholar] [CrossRef]
- RCPCH. Guidance: Paediatric Multisystem Inflammatory Syndrome Temporally Associated with COVID-19. Available online: https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims-guidance (accessed on 13 October 2022).
- Conrad, M.A.; Rosh, J.R. Pediatric Inflammatory Bowel Disease. Pediatr. Clin. N. Am. 2017, 64, 577–591. [Google Scholar] [CrossRef] [PubMed]
- Rosen, M.J.; Dhawan, A.; Saeed, S.A. Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr. 2015, 169, 1053–1060. [Google Scholar] [CrossRef] [Green Version]
- Ashton, J.J.; Barakat, F.M.; Barnes, C.; Coelho, T.A.F.; Batra, A.; Afzal, N.A.; Beattie, R.M. Incidence and Prevalence of Paediatric Inflammatory Bowel Disease Continues to Increase in the South of England. J. Pediatr. Gastroenterol. Nutr. 2022, 75, e20–e24. [Google Scholar] [CrossRef] [PubMed]
- Ruan, W.; Nguyen, H.; Wyatt, A.; Ihekweazu, F.; Vartabedian, B.S.; Karam, L.; Walsh, S.; Kellermayer, R. High Seroconversion Rate Against Severe Acute Respiratory Syndrome Coronavirus 2 in Symptomatic Pediatric Inflammatory Bowel Disease Patients. J. Pediatr. Gastroenterol. Nutr. 2021, 73, 363–366. [Google Scholar] [CrossRef] [PubMed]
- Hisamatsu, T. Management of inflammatory bowel disease during the COVID-19 pandemic. Immunol. Med. 2022, 45, 128–135. [Google Scholar] [CrossRef] [PubMed]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009, 339, b2535. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stewart, L.A.; Clarke, M.; Rovers, M.; Riley, R.D.; Simmonds, M.; Stewart, G.; Tierney, J.F. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: The PRISMA-IPD Statement. Jama 2015, 313, 1657–1665. [Google Scholar] [CrossRef] [PubMed]
- Arrigo, S.; Alvisi, P.; Banzato, C.; Bramuzzo, M.; Celano, R.; Civitelli, F.; D′Arcangelo, G.; Dilillo, A.; Dipasquale, V.; Felici, E.; et al. Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group. Dig. Liver Dis. 2021, 53, 283–288. [Google Scholar] [CrossRef] [PubMed]
- Brenner, E.J.; Pigneur, B.; Focht, G.; Zhang, X.; Ungaro, R.C.; Colombel, J.F.; Turner, D.; Kappelman, M.D.; Ruemmele, F.M. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases. Clin. Gastroenterol. Hepatol. 2021, 19, 394–396.e395. [Google Scholar] [CrossRef] [PubMed]
- Brenner, E.J.; Ungaro, R.C.; Gearry, R.B.; Kaplan, G.G.; Kissous-Hunt, M.; Lewis, J.D.; Ng, S.C.; Rahier, J.F.; Reinisch, W.; Ruemmele, F.M.; et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology 2020, 159, 481–491.e483. [Google Scholar] [CrossRef] [PubMed]
- Bosa, L.; Di Chiara, C.; Gaio, P.; Cosma, C.; Padoan, A.; Cozzani, S.; Perilongo, G.; Plebani, M.; Giaquinto, C.; Donà, D.; et al. Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease. Front. Pediatr. 2022, 10, 815857. [Google Scholar] [CrossRef] [PubMed]
- D′Arcangelo, G.; Distante, M.; Raso, T.; Rossetti, D.; Catassi, G.; Aloi, M. Safety of Biological Therapy in Children With Inflammatory Bowel Disease. J. Pediatr. Gastroenterol. Nutr. 2021, 72, 736–741. [Google Scholar] [CrossRef]
- Koletzko, L.; Klucker, E.; Le Thi, T.G.; Breiteneicher, S.; Rubio-Acero, R.; Neuhaus, L.; Stark, R.G.; Standl, M.; Wieser, A.; Török, H.; et al. Following Pediatric and Adult IBD Patients through the COVID-19 Pandemic: Changes in Psychosocial Burden and Perception of Infection Risk and Harm over Time. J. Clin. Med. 2021, 10, 4124. [Google Scholar] [CrossRef] [PubMed]
- Queiroz, N.S.F.; Martins, C.D.A.; Quaresma, A.B.; Hino, A.A.F.; Steinwurz, F.; Ungaro, R.C.; Kotze, P.G. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry. J. Gastroenterol. Hepatol. 2021, 36, 3033–3040. [Google Scholar] [CrossRef] [PubMed]
- Spencer, E.A.; Klang, E.; Dolinger, M.; Pittman, N.; Dubinsky, M.C. Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients. Inflamm. Bowel Dis. 2021, 27, 1862–1864. [Google Scholar] [CrossRef] [PubMed]
- Magalhães, T.; Granado, M.C.; Manuel, A.R.; Espinheira, M.D.C.; Trindade, E. Impact of COVID-19 in Pediatric Patients and Young Adults with Inflammatory Bowel Disease. GE Port. J. Gastroenterol. 2022, 20, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Martinelli, M.; Strisciuglio, C.; Fedele, F.; Miele, E.; Staiano, A. Clinical and Psychological Issues in Children with Inflammatory Bowel Disease During COVID-19 Pandemic. Inflamm. Bowel Dis. 2020, 26, e95–e96. [Google Scholar] [CrossRef] [PubMed]
- Sansotta, N.; Norsa, L.; Zuin, G.; Panceri, R.; Dilillo, D.; Pozzi, E.; Giacomo, C.; Moretti, C.; Celano, R.; Nuti, F.; et al. Children With Inflammatory Bowel Disease in the COVID-19 Main Endemic Focus: The Lombardy Experience. Front. Pediatr. 2021, 9, 607285. [Google Scholar] [CrossRef]
- Dolinger, M.T.; Person, H.; Smith, R.; Jarchin, L.; Pittman, N.; Dubinsky, M.C.; Lai, J. Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab. J. Pediatr. Gastroenterol. Nutr. 2020, 71, 153–155. [Google Scholar] [CrossRef] [PubMed]
- Turner, D.; Huang, Y.; Martín-de-Carpi, J.; Aloi, M.; Focht, G.; Kang, B.; Zhou, Y.; Sanchez, C.; Kappelman, M.D.; Uhlig, H.H.; et al. Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition. J. Pediatr. Gastroenterol. Nutr. 2020, 70, 727–733. [Google Scholar] [CrossRef] [PubMed]
- Tripathi, K.; Godoy Brewer, G.; Thu Nguyen, M.; Singh, Y.; Saleh Ismail, M.; Sauk, J.S.; Parian, A.M.; Limketkai, B.N. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Inflamm. Bowel Dis. 2022, 28, 1265–1279. [Google Scholar] [CrossRef]
- Gilissen, L.P.L.; Heinen, S.G.H.; Rijpma-Jacobs, L.; Schoon, E.; Schreuder, R.M.; Wensing, A.M.; van der Ende-van Loon, M.C.M.; Bloemen, J.G.; Stapelbroek, J.M.; Stronkhorst, A. Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: An observational Dutch cohort study. Clin. Exp. Med. 2022, 22, 465–476. [Google Scholar] [CrossRef] [PubMed]
- Body-Malapel, M.; Djouina, M.; Waxin, C.; Langlois, A.; Gower-Rousseau, C.; Zerbib, P.; Schmidt, A.M.; Desreumaux, P.; Boulanger, E.; Vignal, C. The RAGE signaling pathway is involved in intestinal inflammation and represents a promising therapeutic target for Inflammatory Bowel Diseases. Mucosal Immunol. 2019, 12, 468–478. [Google Scholar] [CrossRef] [PubMed]
- Rojas, A.; Schneider, I.; Lindner, C.; Gonzalez, I.; Morales, M. Receptor for advanced glycation end-products axis and coronavirus disease 2019 in inflammatory bowel diseases: A dangerous liaison? World J. Gastroenterol. 2021, 27, 2270–2280. [Google Scholar] [CrossRef]
- Alrashed, F.; Alasfour, H.; Shehab, M. Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis. JGH Open 2022, 6, 241–250. [Google Scholar] [CrossRef]
- Coldewey, S.M.; Neu, C.; Bloos, F.; Baumbach, P.; Schumacher, U.; Bauer, M.; Reuken, P.; Stallmach, A. Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): Protocol for a randomised, controlled, multicentre, open-label phase II clinical study. Trials 2022, 23, 737. [Google Scholar] [CrossRef]
- CDC. Multisystem Inflammatory Syndrome (MIS). Available online: https://www.cdc.gov/mis/index.html (accessed on 9 October 2022).
- Hoste, L.; Van Paemel, R.; Haerynck, F. Multisystem inflammatory syndrome in children related to COVID-19: A systematic review. Eur. J. Pediatr. 2021, 180, 2019–2034. [Google Scholar] [CrossRef]
- Penner, J.; Abdel-Mannan, O.; Grant, K.; Maillard, S.; Kucera, F.; Hassell, J.; Eyre, M.; Berger, Z.; Hacohen, Y.; Moshal, K. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: A retrospective cohort study. Lancet. Child Adolesc. Health 2021, 5, 473–482. [Google Scholar] [CrossRef]
- Krawiec, P.; Opoka-Winiarska, V.; Pac-Kożuchowska, E. Is It Inflammatory Bowel Disease Flare or Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19? J. Clin. Med. 2022, 11, 2765. [Google Scholar] [CrossRef] [PubMed]
- Sweeny, K.F.; Zhang, Y.J.; Crume, B.; Martz, C.A.; Blessing, M.M.; Kahn, S.A. Inflammatory Bowel Disease Presenting With Concurrent COVID-19 Multisystem Inflammatory Syndrome. Pediatrics 2021, 147, e2020027763. [Google Scholar] [CrossRef]
- Gavrilescu, O.; Prelipcean, C.C.; Dranga, M.; Popa, I.V.; Mihai, C. Impact of COVID-19 Pandemic on the Quality of Life of IBD Patients. Medicina 2022, 58, 562. [Google Scholar] [CrossRef] [PubMed]
- Fedele, F.; Martinelli, M.; Strisciuglio, C.; Dolce, P.; Giugliano, F.P.; Scarpato, E.; Staiano, A.; Miele, E. Health related quality of life in pediatric Inflammatory bowel disease during COVID-19 pandemic: A prospective study. J. Pediatr. Gastroenterol. Nutr. 2022, 75, 595–600. [Google Scholar] [CrossRef] [PubMed]
- Dorfman, L.; Nassar, R.; Binjamin Ohana, D.; Oseran, I.; Matar, M.; Shamir, R.; Assa, A. Pediatric inflammatory bowel disease and the effect of COVID-19 pandemic on treatment adherence and patients’ behavior. Pediatr. Res. 2021, 90, 637–641. [Google Scholar] [CrossRef] [PubMed]
- Trindade, I.A.; Ferreira, N.B. COVID-19 Pandemic′s Effects on Disease and Psychological Outcomes of People With Inflammatory Bowel Disease in Portugal: A Preliminary Research. Inflamm. Bowel Dis. 2021, 27, 1224–1229. [Google Scholar] [CrossRef] [PubMed]
- Gupta, R.; Beg, S.; Jain, A.; Bhatnagar, S. Paediatric COVID-19 and the GUT. Indian J. Med. Microbiol. 2020, 38, 261–264. [Google Scholar] [CrossRef]
- Lev-Tzion, R.; Focht, G.; Lujan, R.; Mendelovici, A.; Friss, C.; Greenfeld, S.; Kariv, R.; Ben-Tov, A.; Matz, E.; Nevo, D.; et al. COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation. Clin. Gastroenterol. Hepatol. 2022, 20, e1263–e1282. [Google Scholar] [CrossRef] [PubMed]
- Weaver, K.N.; Zhang, X.; Dai, X.; Watkins, R.; Adler, J.; Dubinsky, M.C.; Kastl, A.; Bousvaros, A.; Strople, J.A.; Cross, R.K.; et al. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID. Inflamm. Bowel Dis. 2022, 28, 1497–1505. [Google Scholar] [CrossRef] [PubMed]
- Weaver, K.N.; Kappelman, M.D.; Long, M.D. COVID-19 Vaccination Among Individuals With Inflammatory Bowel Disease: Perception, Efficacy, and Safety Gastroenterol. Hepatol. 2022, 18, 388. [Google Scholar]
- Cotugno, N.; Franzese, E.; Angelino, G.; Amodio, D.; Romeo, E.F.; Rea, F.; Faraci, S.; Tambucci, R.; Profeti, E.; Manno, E.C.; et al. Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens. Vaccines 2022, 10, 1109. [Google Scholar] [CrossRef]
- Lee, K.J.; Choi, S.Y.; Lee, Y.M.; Kim, H.W. Neutralizing Antibody Response, Safety, and Efficacy of mRNA COVID-19 Vaccines in Pediatric Patients with Inflammatory Bowel Disease: A Prospective Multicenter Case-Control Study. Vaccines 2022, 10, 1265. [Google Scholar] [CrossRef] [PubMed]
- Kastl, A.J.; Weaver, K.N.; Zhang, X.; Strople, J.A.; Adler, J.; Dubinsky, M.C.; Bousvaros, A.; Watkins, R.; Dai, X.; Chen, W.; et al. Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease. Am. J. Gastroenterol. 2022. [Google Scholar] [CrossRef]
- Lee, Y.J.; Kim, S.E.; Park, Y.E.; Chang, J.Y.; Song, H.J.; Kim, D.H.; Yang, Y.J.; Kim, B.C.; Lee, J.G.; Yang, H.C.; et al. SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: Expert consensus statement by KASID. Intest. Res. 2022, 20, 171–183. [Google Scholar] [CrossRef] [PubMed]
- Siegel, C.A.; Melmed, G.Y.; McGovern, D.P.; Rai, V.; Krammer, F.; Rubin, D.T.; Abreu, M.T.; Dubinsky, M.C. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: Recommendations from an international consensus meeting. Gut 2021, 70, 635–640. [Google Scholar] [CrossRef] [PubMed]
- Cascini, F.; Pantovic, A.; Al-Ajlouni, Y.; Failla, G.; Ricciardi, W. Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: A systematic review. EClinicalMedicine 2021, 40, 101113. [Google Scholar] [CrossRef] [PubMed]
- Crespo, R.F.; Shafat, M.; Melas-Kyriazi, N.; Gould, L.; Jones, S.; Neves, A.L.; Leis, M.S.; Maheswaran, H.; Darzi, A. International attitudes on COVID-19 vaccination: Repeat national cross-sectional surveys across 15 countries. medRxiv 2021. [Google Scholar] [CrossRef]
- Dalal, R.S.; McClure, E.; Marcus, J.; Winter, R.W.; Hamilton, M.J.; Allegretti, J.R. COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2021, 19, 1730–1732.e1732. [Google Scholar] [CrossRef]
- Costantino, A.; Noviello, D.; Conforti, F.S.; Aloi, M.; Armuzzi, A.; Bossa, F.; Ficari, F.; Leone, S.; Manguso, F.; Mocci, G.; et al. COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients’ Association. Inflamm. Bowel Dis. 2022, 28, 474–478. [Google Scholar] [CrossRef] [PubMed]
- Wu, X.; Lin, J.; Buch, H.; Ding, Q.; Zhang, F.; Cui, B.; Ji, G. The COVID-19 Vaccination Hesitancy Among the People With Inflammatory Bowel Disease in China: A Questionnaire Study. Front. Public Health 2021, 9, 731578. [Google Scholar] [CrossRef] [PubMed]
- Drouin, O.; Fontaine, P.; Arnaud, Y.; Montmarquette, C.; Prud’homme, A.; Da Silva, R.B. Parental decision and intent towards COVID-19 vaccination in children with asthma: An econometric analysis. BMC Public Health 2022, 22, 1547. [Google Scholar] [CrossRef] [PubMed]
- Temsah, M.H.; Alhuzaimi, A.N.; Aljamaan, F.; Bahkali, F.; Al-Eyadhy, A.; Alrabiaah, A.; Alhaboob, A.; Bashiri, F.A.; Alshaer, A.; Temsah, O.; et al. Parental Attitudes and Hesitancy About COVID-19 vs. Routine Childhood Vaccinations: A National Survey. Front. Public Health 2021, 9, 752323. [Google Scholar] [CrossRef] [PubMed]
- Yılmaz, M.; Sahin, M.K. Parents’ willingness and attitudes concerning the COVID-19 vaccine: A cross-sectional study. Int. J. Clin. Pract. 2021, 75, e14364. [Google Scholar] [CrossRef]
- Huang, Y.; Su, X.; Xiao, W.; Wang, H.; Si, M.; Wang, W.; Gu, X.; Ma, L.; Li, L.; Zhang, S.; et al. COVID-19 vaccine hesitancy among different population groups in China: A national multicenter online survey. BMC Infect. Dis. 2022, 22, 153. [Google Scholar] [CrossRef] [PubMed]
- Tangcharoensathien, V.; Calleja, N.; Nguyen, T.; Purnat, T.; D′Agostino, M.; Garcia-Saiso, S.; Landry, M.; Rashidian, A.; Hamilton, C.; AbdAllah, A.; et al. Framework for Managing the COVID-19 Infodemic: Methods and Results of an Online, Crowdsourced WHO Technical Consultation. J. Med. Internet Res. 2020, 22, e19659. [Google Scholar] [CrossRef] [PubMed]
- Bao, H.; Cao, B.; Xiong, Y.; Tang, W. Digital Media’s Role in the COVID-19 Pandemic. JMIR mHealth uHealth 2020, 8, e20156. [Google Scholar] [CrossRef]
Author | Country | Total IBD Patient (No) | Total IBD Patient with COVID-19 (No) | No Need for Hospitalization (No) | Hospitalization (No) | ICU Admission (No) | Deaths (No) | CD (No) | UC (No) | Mean/ Median, Age (yrs) | Mean Outcomes |
---|---|---|---|---|---|---|---|---|---|---|---|
Arrigo et al., 2020, [12] | Italy | 2291 | 6 | 5 | 1 | 0 | 0 | 2 | 4 | 13.5 | Mild symptoms—1 severe infection |
Brenner et al., 2021 [13] | 23 countries—USA, France, Italy, Argentina, UK, | 209 | 209 | 195 | 14 | 2 | 0 | 138 | 61 | 15/16 | Mild symptoms—14 hospitalized—2 PICU |
Brenner et al., 2020 [14] | 33 countries | 29 | 29 | 26 | 3 | 0 | 0 | N/A | N/A | 0–19 | Mild symptoms—3 severe infection |
D’Arcangelo et al., 2021 [16] | Italy | 185 | 4 | 4 | 0 | 0 | 0 | 2 | 2 | N/A | 2 asymptomatic—2 mild symptoms |
Bosa et al., 2022 [15] | Italy | 84 | 12 | 12 | 0 | 0 | 0 | 9 | 1 | 14/1–18 | 4 asymptomatic—8 mild symptoms |
Koletzko et al., 2021 [17] | Germany | 89 | 25 | 25 | 0 | 0 | 0 | 44 | 34 | 6–20 | Mild symptoms |
Queiroz et al., 2021 [18] | Latin America (13 countries) | 18 | 18 | 17 | 1 | 0 | 0 | N/A | N/A | 0–18 | Mild symptoms |
Dolinger et al., 2020 [23] | USA | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 14 | Severe symptoms |
Spencer et al., 2021 [19] | USA | 340 | 51 | N/A | N/A | 0 | 0 | 39 | 9 | 0–21 | N/A |
Ruan et al., 2021 [8] | USA | 14 | 14 | 14 | 0 | 0 | 0 | 10 | 4 | N/A | 7 transient symptoms—5 asymptomatic |
Μagalhaes et al., 2021 [20] | Portugal | 268 | 11 | 11 | 0 | 0 | 0 | 7 | 4 | 15 (7–18) | 100% mild disease—no complication |
Turner et al., 2020 [24] | Portugal-Global study | 8 | 8 | 8 | 0 | 0 | 5 | 2 | N/A | 100% mild disease—no complication | |
Martinelli et al., 2020 [21] | Italy | 180 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | No COVID-19 cases | |
Sansotta et al., 2021 [22] | Italy | 290 | 2 | 2 | 0 | 0 | 0 | 0 | 2 | 15.2 (2–18) | 100% mild disease—no complication |
Arrigo et al., 2020, [12] | Brenner et al., 2020 [14] | Brenner et al., 2021 [13] | Dolinger et al., 2020 [23] | Queiroz et al., 2021 [18] | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total IBD Patient (No) | 2291 | 29 | 209 | 1 | 18 | ||||||||
Total IBD patient with COVID-19 (No) | 6 | 29 | 209 | 1 | 18 | ||||||||
No need for hospitalization (No) | 5 | 26 | 195 | 0 | 17 | ||||||||
Hospitalization (No) | 1 | 3 | 14 | 1 | 1 | ||||||||
IBD activity | Treatment | IBD activity | Treatment | IBD activity | Treatment | IBD activity | Treatment | IBD activity | Treatment | ||||
remission | azathioprine | N/A | N/A | mild | 3 | Sulfasalazine/mesalamine | 8 | severe | infliximab | N/A | N.A | ||
moderate | 8 | Steroids | 4 | ||||||||||
severe | 1 | 6MP/azathioprine monotherapyc | 2 | ||||||||||
remission | 1 | Methotrexate monotherapyc | 0 | ||||||||||
unknown | 1 | TNF antagonist | 1 | ||||||||||
TNF antagonist/ 6MP/AZA/MTX | 2 | ||||||||||||
Anti-integrin (vedolizumab) | 2 | ||||||||||||
IL12/23 inhibitor | 2 | ||||||||||||
Janus kinase inhibitor | 0 | ||||||||||||
Other IBD medication(s) | 1 | ||||||||||||
No IBD medication | 1 | ||||||||||||
ICU admission (No) | 0 | 0 | 2 | 0 | 0 | ||||||||
IBD activity | Treatment | IBD activity | Treatment | IBD activity | Treatment | IBD activity | Treatment | IBD activity | Treatment | ||||
- | - | - | - | unknown | 1 | Sulfasalazine/Mesalamine | 2 | - | - | - | - | ||
moderate | 1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Batsiou, A.; Mantzios, P.; Piovani, D.; Tsantes, A.G.; Kopanou Taliaka, P.; Liakou, P.; Iacovidou, N.; Tsantes, A.E.; Bonovas, S.; Sokou, R. SARS-CoV-2 Infection and Outcomes in Children with Inflammatory Bowel Diseases: A Systematic Review. J. Clin. Med. 2022, 11, 7238. https://doi.org/10.3390/jcm11237238
Batsiou A, Mantzios P, Piovani D, Tsantes AG, Kopanou Taliaka P, Liakou P, Iacovidou N, Tsantes AE, Bonovas S, Sokou R. SARS-CoV-2 Infection and Outcomes in Children with Inflammatory Bowel Diseases: A Systematic Review. Journal of Clinical Medicine. 2022; 11(23):7238. https://doi.org/10.3390/jcm11237238
Chicago/Turabian StyleBatsiou, Anastasia, Petros Mantzios, Daniele Piovani, Andreas G. Tsantes, Paschalia Kopanou Taliaka, Paraskevi Liakou, Nicoletta Iacovidou, Argirios E. Tsantes, Stefanos Bonovas, and Rozeta Sokou. 2022. "SARS-CoV-2 Infection and Outcomes in Children with Inflammatory Bowel Diseases: A Systematic Review" Journal of Clinical Medicine 11, no. 23: 7238. https://doi.org/10.3390/jcm11237238
APA StyleBatsiou, A., Mantzios, P., Piovani, D., Tsantes, A. G., Kopanou Taliaka, P., Liakou, P., Iacovidou, N., Tsantes, A. E., Bonovas, S., & Sokou, R. (2022). SARS-CoV-2 Infection and Outcomes in Children with Inflammatory Bowel Diseases: A Systematic Review. Journal of Clinical Medicine, 11(23), 7238. https://doi.org/10.3390/jcm11237238